Key result
PCSK9 genetic variants show conflicting links to breast cancer survival, challenging its role as a therapeutic target.
Why the study?
Does PCSK9 affect breast cancer survival in breast cancer patients?
Does PCSK9 affect breast cancer survival in breast cancer patients?
Methodological discrepancies must be resolved before considering PCSK9 as a therapeutic target in breast cancer patients.
Potential reasons for the discrepant results are different genetic models, sample selection criteria, and the time-variability of HR estimates. They should be explored before considering PCSK9 a therapeutic target in BC patients.
No takes yet. Share an insight, caveat, or question.
Pott et al. (2026) studied this question. PCSK9 genetic variants yield discrepant results regarding breast cancer survival, requiring further exploration before considering PCSK9 a therapeutic target in breast cancer patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: